First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

Dean F. Bajorin,Johannes Alfred Witjes,Jurgen Gschwend,Michael Schenker,Begona P. Valderrama,Yoshihiko Tomita,Aristotelis Bamias,Thierry Lebret,Shahrokh Shariat,Se Hoon Park,Ye Dingwei,Mads Agerbaek,Sandra Collette,Keziban Unsal-Kacmaz,Dimitrios Zardavas,Henry B. Koon,Matt D. Galsky

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 44|浏览29

暂无评分

摘要

391Background: The standard of care (SOC) for patients (pts) with MIUC is radical surgery ± cisplatin-based neoadjuvant chemotherapy (chemo), but many pts are cisplatin-ineligible. There is no conc...

查看译文

关键词

Neoadjuvant Therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要